TLR4 and the microbiome in CCM disease
TLR4 and the microbiome in CCM disease
批准号:
10152688
负责人:
MARK L KAHN
金额:
$53.96万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2022-04-30
关键词:
AbscessAddressAdultAffectAnimal ModelAnimalsAntibiotic TherapyAntibodiesAntsBacteroidetesBindingBloodBrainCCM1 geneCD14 AntigenCD14 geneCell membraneCerebrovascular DisordersColitisComplexDiseaseDisease susceptibilityEndotheliumExcisionFDA approvedFecesFoundationsFutureGenesGeneticGenomic approachGerm-FreeGram-Negative BacteriaGrowthHousingHumanInbreedingIndividualInflammatoryLesionLigandsLipopolysaccharidesMedicalMetagenomicsModelingMolecularMusMutationNeonatalOperative Surgical ProceduresPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPredispositionProteinsReceptor SignalingResearch PersonnelResistanceRoleSeizuresSeverity of illnessShotgunsSignal PathwaySignal TransductionSingle Nucleotide PolymorphismSourceStrokeTLR4 geneTestingTranslatingbasebrain endothelial cellcerebral cavernous malformationseffective therapyefficacy testingexperimental studygastrointestinal epitheliumgenetic analysisgenetic approachgenetic associationgut bacteriagut microbiomehuman subjectin vivometabolomicsmicrobiomemouse geneticsmouse modelneonatal miceneonateneurovascularnon-geneticnovelnovel therapeutic interventionnovel therapeuticspreventreceptorresponsetherapeutic targettranscription factortranslational impact
中文摘要
脑海绵状血管畸形(CCM)是一种脑血管疾病,
在美国有20万人,是年轻人中风和癫痫发作的常见原因。
个体目前还没有针对CCM疾病的医学疗法,并且治疗是非常困难的。
仅限于手术切除和抗癫痫药物。我们最近
证明CCM的出现是由于MEKK 3信号的增加,
CCM缺陷脑内皮细胞中KLF 2和KLF 4转录因子的表达
细胞(EC)。这些研究揭示了下游信号传导机制的影响,
CCM疾病,但他们没有确定强有力的治疗靶点或解决问题
是什么激活了脑内皮细胞中的MEKK 3。我们的初步研究表明,TLR 4
是内皮细胞MEKK 3-KLF信号传导的关键上游激活剂,
CCM形成,而肠道微生物组中的革兰氏阴性菌(GNB)是
小鼠新生儿CCM模型中该途径的关键体内配体。遗传分析
我们的合作研究者Helen Kim博士独立地对人类CCM患者进行了研究,
将TLR 4及其共受体CD 14鉴定为与CCM病变数量相关的基因,
这表明我们的小鼠发现延伸到人类CCM疾病。这项建议会
进一步测试内皮TLR 4信号传导和肠道微生物组在CCM中的作用
使用小鼠和人类研究的疾病发病机制。目标1将(一)检验以下方面的作用:
(ii)确定阻断抗-TLR 4和抗-TLR 4抗体是否在成年小鼠CCM形成过程中起作用,
抗CD 14抗体在小鼠模型中防止CCM形成,(iii)使用小鼠
遗传学方法来确定TLR 4激活MEKK 3的途径,
CCM形成,和(iv)应用遗传方法来充分询问TLR 4-MEKK 3-
由于KRIT 1中的常见突变,CCM疾病患者中的KLF通路。
目的2将通过以下方式测试GNB和肠道微生物组在CCM发病机制中的作用:(i)
确定CCM病变是否出现在无菌动物中,(ii)定义微生物组
其赋予小鼠对CCM疾病的抗性或易感性,以及(iii)测试是否
肠上皮屏障的破坏加速了小鼠中CCM的形成。这些
研究将大大扩展我们对分子和生理的理解,
CCM发病机制的基础,并为将这些发现转化为
基于阻断TLR 4信号传导的CCM疾病的新疗法(FDA
已经存在批准的药剂)或改变肠道微生物组。
英文摘要
Cerebral cavernous malformation (CCM) is a cerebrovascular disease that affects over
200,000 individuals in the US and is a common cause of stroke and seizure in young
individuals. There are presently no medical therapies for CCM disease, and treatment is
limited to surgical resection and anti-seizure medications. We have recently
demonstrated that CCMs arise due to a gain of MEKK3 signaling and increased
expression of the KLF2 and KLF4 transcription factors in CCM-deficient brain endothelial
cells (ECs). These studies reveal the downstream signaling mechanism impacted in
CCM disease, but they do not identify strong therapeutic targets or address the question
of what activates MEKK3 in brain ECs. Our preliminary studies demonstrate that TLR4
is a critical upstream activator of endothelial MEKK3-KLF signaling that is required for
CCM formation, and that gram negative bacteria (GNB) in the gut microbiome are the
key in vivo ligand for this pathway in the mouse neonatal CCM model. Genetic analysis
of human CCM patients by our co-investigator Dr. Helen Kim has independently
identified TLR4 and its co-receptor CD14 as genes associated with CCM lesion number,
suggesting that our mouse findings extend to human CCM disease. This proposal will
further test the role of endothelial TLR4 signaling and the gut microbiome in CCM
disease pathogenesis using mouse and human studies. Aim 1 will (i) test the role of
TLR4 during CCM formation in adult mice, (ii) determine whether blocking ant-TLR4 and
anti-CD14 antibodies prevent CCM formation in the mouse model, (iii) use mouse
genetic approaches to determine the pathway by which TLR4 activates MEKK3 during
CCM formation, and (iv) apply genetic approaches to fully interrogate the TLR4-MEKK3-
KLF pathway in human patients with CCM disease due to a common mutation in KRIT1.
Aim 2 will test the role of GNB and the gut microbiome in CCM pathogenesis by (i)
determining whether CCM lesions arise in germ-free animals, (ii) defining microbiomes
that confer resistance or susceptibility to CCM disease in mice, and (iii) testing whether
breakdown of the gut epithelial barrier accelerates CCM formation in mice. These
studies will significantly expand our understanding of the molecular and physiologic
basis of CCM pathogenesis, and lay the foundation for translating these discoveries to
new therapies for CCM disease based on blocking TLR4 signaling (for which FDA
approved agents already exist) or altering the gut microbiome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic Investigation of Covid 19 in Lung Disease
-
批准号:10673004
-
项目类别:
-
资助金额:$90.87万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
-
批准号:10417684
-
项目类别:
-
资助金额:$59.82万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Genetic Investigation of Covid 19 in Lung Disease
-
批准号:10502908
-
项目类别:
-
资助金额:$92.28万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Genetic Investigation of Covid 19 in Lung Disease
-
批准号:10768221
-
项目类别:
-
资助金额:$16.89万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
-
批准号:10608143
-
项目类别:
-
资助金额:$60.63万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Molecular and genetic basis of deep venous thrombosis
-
批准号:10460687
-
项目类别:
-
资助金额:$35.88万
-
财政年份:2021
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10226236
-
项目类别:
-
资助金额:$72.28万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10626893
-
项目类别:
-
资助金额:$70.3万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10033435
-
项目类别:
-
资助金额:$72.58万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10408810
-
项目类别:
-
资助金额:$71.72万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
MEKK3 signaling in hemogenic endothelium
-
批准号:10198023
-
项目类别:
-
资助金额:$76.08万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
Molecular and genetic basis of deep venous thrombosis
-
批准号:10200879
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
Molecular and genetic basis of deep venous thrombosis
-
批准号:10225228
-
项目类别:
-
资助金额:$42.03万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
MEKK3 signaling in hemogenic endothelium
-
批准号:9765393
-
项目类别:
-
资助金额:$80.72万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
TLR4 and the microbiome in CCM disease
-
批准号:9912850
-
项目类别:
-
资助金额:$56.57万
-
财政年份:2017
-
负责人:MARK L KAHN
-
依托单位:
TLR4 and the microbiome in CCM disease
-
批准号:9287514
-
项目类别:
-
资助金额:$60.08万
-
财政年份:2017
-
负责人:MARK L KAHN
-
依托单位:
Downstream molecular mechanisms underlying cerebral cavernous malformation
-
批准号:10220147
-
项目类别:
-
资助金额:$31.47万
-
财政年份:2015
-
负责人:MARK L KAHN
-
依托单位:
Downstream molecular mechanisms underlying cerebral cavernous malformation
-
批准号:10417156
-
项目类别:
-
资助金额:$31.18万
-
财政年份:2015
-
负责人:MARK L KAHN
-
依托单位:
Downstream molecular mechanisms underlying cerebral cavernous malformation
-
批准号:10621255
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2015
-
负责人:MARK L KAHN
-
依托单位:
Genetic Investigation of pulmonary lymphatic development and function
-
批准号:8761251
-
项目类别:
-
资助金额:$41.57万
-
财政年份:2014
-
负责人:MARK L KAHN
-
依托单位:
海外基金